A new achievement in cell therapy area was reached by the professional team of Virginia Contract Research Organization Co., Ltd. (VCRO).
The VCRO team was commissioned by the client to submit an application for FDA orphan drug designation. During the process, the VCRO team assisted in integrating the research results of heterologous CAR-T cell solid tumor therapy and completed the writing of the application documents, successfully obtaining FDA approval and qualification.
VCRO has successfully served its cell therapy clients to expand emerging cancer treatments. In the many fields of cell therapy, VCRO is expanding with you!